VTX-2337

Known as: TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337 
A small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities. TLR8 agonist VTX-2337 binds to… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
02420112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purpose: As Toll-like receptors (TLR) are key mediators of immune responses, TLR agonists may be important for augmenting the… (More)
Is this relevant?
2016
2016
UNLABELLED VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
PURPOSE Immunotherapy as a treatment for cancer holds the promise of complete and durable tumor remission, yet the… (More)
Is this relevant?
2014
2014
PURPOSE This phase I, open-label, uncontrolled, ascending-dose study explored the safety, maximum tolerated dose (MTD… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2014
2014
Purpose: This phase I, open-label, uncontrolled, ascending-dose study explored the safety, maximum tolerated dose (MTD… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2013
2013
Cetuximab is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody that prolongs survival in the treatment for head… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
NK cells express an array of activating and inhibitory receptors, which facilitate the recognition and lysis of virally infected… (More)
Is this relevant?
2012
2012
PURPOSE We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2011
2011
2537 Background: Toll-like receptors (TLRs) have emerged as attractive targets for anti-cancer immunotherapies. VTX-2337 is a… (More)
Is this relevant?